NasdaqHealth CarePharmaceutical PreparationsSEATTLE, WA

Aptevo Therapeutics Inc. APVO

Ask your AI

Estimated market cap $1.07M1.80M shares, shares as of Aug 14, 2026CIK 1671584

Insider trades, 12 mo

—

No open-market trades

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

16.1% of shares · 0 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q2 2026

What changed in Aptevo Therapeutics Inc.'s latest quarterly report, compared with the one before.

Filed Aug 14, 2026 · Quarter ended Jun 30, 2026

Compared with the 10-Q for the quarter ended Mar 31, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Aptevo Therapeutics Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Nov 10, 2025. Insiders have two business days to file.

Recent insider trades
Insider	Traded	Type	Value	Since trade
Grady Grant III Director	Nov 10, 2025 Form 4 ↗	Buy	+$20.1K 13,513 sh @ $1.49	-108.6%

All APVO insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

290,716 shares

8 funds report APVO. Values checked against market prices.

Funds own 2.8% of shares (Q2 2026)

9 funds hold the stock.

Q3 2026: 16% · 5,560 of ~8,900 funds reported so far

Q4 20252.2%
Q1 20264.5%
Q2 20262.8%
Q3 2026 (so far)16%

Q3 2026. 3 new, 0 added to, 1 trimmed, 4 exited since Q2 2026.

Top 13F holders
#
1	Sabby Management, LLC 13F ↗	232,692	$423.5K	New
2	Hudson Bay Capital Management LP 13F ↗	40,700	$74.1K	New
3	Vanguard Capital Management LLC 13F ↗	12,713	$23.1K	unchanged
4	Vanguard Fiduciary Trust Co 13F ↗	4,142	$7,538	unchanged
5	Osaic Holdings, Inc. 13F ↗	360	$664	unchanged
6	SBI Securities Co., Ltd. 13F ↗	105	$191	-3.7%
7	Caitong International Asset Management Co., Ltd 13F ↗	3	$5	New
8	Danske Bank A/S 13F ↗	1	$2	unchanged

Download CSV Every fund that holds APVO, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Recent congressional trades
Member	Transaction	Amount	Traded → disclosed	Since trade
Steve Cohen D House · TN	Sale	$470.99 Stephens SEP IRA	Jun 24 → Jul 3 ↗ 9d	—

All 1 trade →Free on every plan.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Aptevo Therapeutics Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Aptevo Therapeutics Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report, adjusted for splits

Funds holding the stock by quarter

Q3 2016	1	—	0	$15
Q4 2016	1	0	0	$15
Q4 2025	11	+10	20,299	$191.4K
Q1 2026	9	-2	53,750	$229.7K
Q2 2026	9	0	50,446	$224.3K
Q3 2026	8	-1	290,716	$529.1K

Each point is a quarter-end, from Q3 2016 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (03835L702). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q3 2016) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits (1-for-14 on Mar 27, 2020, 1-for-44 on Mar 6, 2024, 1-for-37 on Dec 4, 2024, 1-for-20 on May 27, 2025, 1-for-18 on Dec 30, 2025): reports from before a split are multiplied by its ratio, so every quarter is on the share count of Q3 2026.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes5 in 12 mo 8-K events11 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive pay3 fiscal years Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials1 active IPO history11 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Aptevo Therapeutics Inc.
Address: 2401 4TH AVE., SUITE 1050, SEATTLE, WA 98121
Phone: 206-838-0500
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company
Incorporated in: DE
Listed as: APVO (Nasdaq)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$0.5941−$0.07 (−10.00%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $0.5941 · High $1.73Nov 13, 2026

Aug 13, 2026Low $0.5941 · High $3.40Nov 13, 2026

Nov 13, 2025Low $0.5941 · High $26.10Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. The stock split 1-for-18 on Dec 30, 2025; earlier prices are shown divided by the split ratio. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.